We hypothesize that high PD-L1 expression may partially restore the efficacy of PD-1 inhibitors by facilitating immune checkpoint interactions between tumor cells and T cells, thereby mitigating the KIF20A-driven oncogenic effects. The gene discussed is KIF20A; the disease is neoplasm.